340B Orphan Drug Rule Overturned In Court, Putting Future Regs Into Question
This article was originally published in The Pink Sheet Daily
Executive Summary
A federal court rules in favor of the Pharmaceutical Research and Manufacturers of America in its lawsuit seeking injunction against the 340B discount program’s orphan drug rule. The rule “must be vacated” because HHS lacks the statutory authority to issue the rule, the judge says, giving rise to questions about how upcoming 340B regs will be affected.
You may also be interested in...
PhRMA Seeking Injunction Against 340B Orphan Drug Exclusion Rule
The trade group files a lawsuit seeking preliminary and permanent injunctions against implementation of a final rule that requires 340B discounts for the non-orphan uses of drugs with an orphan designation.
340B Final Rule Keeps Orphan Drug Exclusion Narrow, Counter To Manufacturers’ Request
HRSA’s final rule on the exclusion of orphan drugs from 340B discounts says the exclusion applies only to the FDA-designated orphan indication, not all uses of a drug with a rare-disease designation.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.